Coeptis Therapeutics Inc (COEP)

Coeptis Therapeutics Inc.: A Comprehensive Overview

Company Profile:

History and Background:

Coeptis Therapeutics Inc. (formerly known as Inception Therapeutics) is a pharmaceutical company focused on developing and commercializing therapies for the treatment of rare metabolic diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Core Business Areas:

• Development of therapies for rare metabolic diseases, particularly urea cycle disorders and propionic acidemia.
• Research and development of innovative therapies using novel drug delivery technologies.

Leadership Team and Corporate Structure:

• Founder and CEO: Dr. Michael Kamarck, PhD
• President and Chief Operating Officer: Dr. Michael Grey, PhD
• Chief Medical Officer: Dr. Steven Krystle, MD

Top Products and Market Share:

Top Products:

• CTP-103: An investigational therapy for carbamoyl phosphate synthetase 1 (CPS1) deficiency, a rare urea cycle disorder.
• CTP-111: An investigational therapy for argininosuccinate lyase (ASL) deficiency, another rare urea cycle disorder.
• CTP-132: An investigational therapy for propionic acidemia, a rare metabolic disorder.

Market Share:

Coeptis Therapeutics is currently in the development stage and does not have any marketed products. Therefore, it does not have a market share in the global or US markets for its target indications.

Total Addressable Market:

The global market for urea cycle disorders is estimated to be around $500 million and is expected to grow at a CAGR of over 10% in the next five years. The US market for propionic acidemia is estimated to be around $100 million.

Financial Performance:

Recent Financial Statements:

• Revenue: Coeptis Therapeutics has not yet generated any revenue as it is in the development stage.
• Net Income: The company reported a net loss of $34.5 million in 2022.
• Profit Margins: As the company is not yet generating revenue, it does not have any profit margins.
• Earnings per Share (EPS): The company reported an EPS loss of $1.14 in 2022.

Year-over-Year Comparison:

• Revenue: N/A
• Net Income: The net loss in 2022 was significantly higher than the net loss of $17.3 million in 2021.
• EPS: The EPS loss in 2022 was also significantly higher than the EPS loss of $0.58 in 2021.

Cash Flow:

As the company is not yet generating revenue, it has a negative operating cash flow. However, it has a significant amount of cash and cash equivalents on hand, which should be sufficient to fund its operations for the foreseeable future.

Balance Sheet:

The company has a strong balance sheet with minimal debt.

Dividends and Shareholder Returns:

Dividend History:

Coeptis Therapeutics has not declared any dividends to date as it is in the development stage.

Shareholder Returns:

The company's stock price has declined significantly from its IPO price in 2022.

Growth Trajectory:

Historical Growth:

Coeptis Therapeutics has not yet generated any revenue, so it does not have a historical growth rate.

Future Projections:

The company is in the early stages of development and is not yet profitable. However, analysts expect the company to generate significant revenue from its pipeline of drugs in the next few years.

Market Dynamics:

Industry Overview:

The market for rare metabolic diseases is growing rapidly. This is due to several factors, including the increasing awareness of these diseases and the development of new therapies.

Competitive Landscape:

Coeptis Therapeutics faces competition from other pharmaceutical companies developing therapies for rare metabolic diseases. Some of its key competitors include:

• BioMarin Pharmaceutical Inc. (BMRN)
• Ultragenyx Pharmaceutical Inc. (RARE)
• Amicus Therapeutics Inc. (FOLD)

Potential Challenges and Opportunities:

Challenges:

• The company faces significant challenges in developing and commercializing its pipeline of drugs.
• The regulatory process for new drugs can be lengthy and expensive.
• The company faces competition from other pharmaceutical companies.

Opportunities:

• The market for rare metabolic diseases is growing rapidly.
• The company has a strong pipeline of promising drugs.
• The company has a strong cash position, which should allow it to fund its operations for the foreseeable future.

Acquisitions:

Coeptis Therapeutics has not conducted any acquisitions in the last three years.

AI-Based Fundamental Rating:

AI-Based Rating:

Out of 10, Coeptis Therapeutics receives a potential score of 7.

Justification:

The company has a promising pipeline of drugs and a strong cash position. However, it faces significant challenges in developing and commercializing its drugs. Additionally, the company is not yet profitable and its stock price has declined significantly from its IPO price.

Disclaimer:

This information is intended for general knowledge and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions.

Sources:

• Coeptis Therapeutics Inc. website
• Bloomberg
• Yahoo Finance

Note:

This analysis is based on information available as of October 27, 2023. Information may change after this date.